Praxis Moves Away From Depression With Surprising Phase II/III Failure

With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Praxis moves away from depression after Phase II/III failure

Praxis Precision Medicines, Inc. revealed a surprising Phase II/III failure for major depression disorder (MDD) candidate PRAX-114 but was praised by analysts for moving quickly to re-center its R&D efforts on mid-stage essential tremor and epilepsy programs.

The company announced on 6 June that its GABA-alpha positive allosteric modulator failed to meet the primary endpoint and also...

More from Clinical Trials

More from R&D

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.